213 related articles for article (PubMed ID: 20354542)
1. Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
Loupakis F; Falcone A
Nat Rev Clin Oncol; 2010 Apr; 7(4):190-1. PubMed ID: 20354542
[TBL] [Abstract][Full Text] [Related]
2. [The new chemotherapy of colorectal cancers].
Taïeb J; Boige V; Ducreux M
Presse Med; 2002 Jan; 31(3):132-8. PubMed ID: 11859739
[TBL] [Abstract][Full Text] [Related]
3. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
4. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Ychou M; Viret F; Kramar A; Desseigne F; Mitry E; Guimbaud R; Delpero JR; Rivoire M; Quénet F; Portier G; Nordlinger B
Cancer Chemother Pharmacol; 2008 Jul; 62(2):195-201. PubMed ID: 17901955
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
[TBL] [Abstract][Full Text] [Related]
7. Second line therapies move to the forefront in colorectal cancer.
Miller M
J Natl Cancer Inst; 1999 Jun; 91(12):998-1000. PubMed ID: 10379961
[No Abstract] [Full Text] [Related]
8. What's new in ... colorectal cancer. Meaningful progress in therapy options.
Polansky M; Ross AC
JAAPA; 2009 Apr; 22(4):51-2. PubMed ID: 19452823
[No Abstract] [Full Text] [Related]
9. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
[TBL] [Abstract][Full Text] [Related]
10. Multicentre study of perioperative
Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
[TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy for colorectal cancers].
Lièvre A; Mitry E
J Chir (Paris); 2003 Feb; 140(1):52-5. PubMed ID: 12709655
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
Martin RC; Scoggins CR; Tomalty D; Schreeder M; Metzger T; Tatum C; Sharma V
J Gastrointest Surg; 2012 Aug; 16(8):1531-8. PubMed ID: 22528576
[TBL] [Abstract][Full Text] [Related]
13. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
Comella P; Massidda B; Natale D; Putzu C; Sandomenico C; Filippelli G; Palmeri S; Condemi G; Vessia G; Barberis G; Ionta MT; Tafuto S; Barbato E
Clin Colorectal Cancer; 2011 Mar; 10(1):42-7. PubMed ID: 21609935
[TBL] [Abstract][Full Text] [Related]
15. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
Grivicich I; Mans DR; Peters GJ; Schwartsmann G
Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
[TBL] [Abstract][Full Text] [Related]
16. [Systemic treatment of colorectal cancers--factual standards and perspectives].
Miron L
Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):752-8. PubMed ID: 14756014
[TBL] [Abstract][Full Text] [Related]
17. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.
Heun JM; Grothey A; Branda ME; Goldberg RM; Sargent DJ
Oncologist; 2011; 16(6):859-67. PubMed ID: 21632455
[TBL] [Abstract][Full Text] [Related]
18. Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
Saif MW
World J Gastroenterol; 2009 Aug; 15(31):3855-64. PubMed ID: 19701965
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
Yim KL; Cunningham D
Nat Rev Clin Oncol; 2009 Oct; 6(10):560-1. PubMed ID: 19786997
[No Abstract] [Full Text] [Related]
[Next] [New Search]